Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Following burosumab treatment, mean (SD) serum 1,25(OH)2D concentration increased significantly at Year 1 and Year 3 (change from baseline: 21.3 [26.4], P < .0001 and 10.1 [20.6], P < .0001, respectively) in the overall cohort, significant increases were seen at Year 1 (21.1 [22.5], P < .0001) and Year 3 (14.2 [20.3], P < .0001) in the pediatric cohort, and in the adult cohort a significant increase was seen at Year 1 (21.5 [29.9], P < .0001) and a non-significant increase was seen at Year 3 (5.9 [20.3], P = .084).

Source: Serum 1,25-dihydroxyvitamin D concentration. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were eligible to be enrolled in the XLH-DMP if they had a confirmed diagnosis of XLH based on characteristic clinical features and a biochemical profile consistent with XLH or if they or an affected family member had a confirmed pathogenic or likely pathogenic PHEX variant.

Source: Methods.

As this is an observational study, no adjustments for multiple comparisons were made; all P-values were considered nominal.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program

Observational study · The Journal of Clinical Endocrinology and Metabolism · 2026

Original publication title

Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program

Leanne M Ward; Thomas O Carpenter; Hamilton Cassinelli; Pablo Florenzano; Erik A Imel; Aliya A Khan; Ben Johnson; Erru Yang; Marc Vincent; Heather M Heerssen; Zhiyi Li; Jill H Simmons

© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This analysis demonstrated the real-world effectiveness of burosumab for XLH, which appears evident across age groups.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To evaluate outcomes up to 3 years following initiation of treatment with anti-FGF23 antibody (burosumab) in a real-world setting among individuals with XLH, stratified by age group, including those excluded from clinical trials (<1, 13-17, and ≥65 years).

Source: Objective

Abstract: What methods does the paper describe?

The XLH Disease Monitoring Program is a prospective, longitudinal, long-term-outcomes program for individuals with XLH. This analysis included participants who were burosumab-naive at baseline and who had initiated burosumab between baseline and the Year 1 visit. Changes from baseline in biochemistry, clinical outcomes, and patient-reported outcomes (PROs) were assessed at Year 1 (Y1) and Year 3 (Y3) visits.

Source: Methods

Abstract: Context

X-linked hypophosphatemia (XLH) is a rare disorder characterized by excess fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia, osteomalacia, and rickets.

Source: Context

Abstract: Results

Among participants (n = 139), burosumab led to significant and sustained improvements in mean (SD) serum phosphate z-scores at Y1 and Y3 (change from baseline: 1.4 [1.1]; P < .0001 for each timepoint). Among pediatric participants, serum alkaline phosphatase z-scores, Rickets Severity Scores, and patient-reported pain interference declined significantly at Y1 and Y3; non-significant changes were observed in fatigue and physical function mobility. Adults showed significant improvements in PRO measures of pain, stiffness, and physical function, with higher proportions of participants achieving minimal clinically important differences at Y3 vs Y1.

Trends observed in overall cohorts were generally consistent across age sub-groups, with statistical significance reached for many endpoints.

Source: Results

Abstract: Conclusion

This analysis demonstrated the real-world effectiveness of burosumab for XLH, which appears evident across age groups.

Source: Conclusion
Authors’ abstract

Abstract

Context

X-linked hypophosphatemia (XLH) is a rare disorder characterized by excess fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia, osteomalacia, and rickets.

Objective

To evaluate outcomes up to 3 years following initiation of treatment with anti-FGF23 antibody (burosumab) in a real-world setting among individuals with XLH, stratified by age group, including those excluded from clinical trials (<1, 13-17, and ≥65 years).

Methods

The XLH Disease Monitoring Program is a prospective, longitudinal, long-term-outcomes program for individuals with XLH. This analysis included participants who were burosumab-naive at baseline and who had initiated burosumab between baseline and the Year 1 visit. Changes from baseline in biochemistry, clinical outcomes, and patient-reported outcomes (PROs) were assessed at Year 1 (Y1) and Year 3 (Y3) visits.

Results

Among participants (n = 139), burosumab led to significant and sustained improvements in mean (SD) serum phosphate z-scores at Y1 and Y3 (change from baseline: 1.4 [1.1]; P < .0001 for each timepoint). Among pediatric participants, serum alkaline phosphatase z-scores, Rickets Severity Scores, and patient-reported pain interference declined significantly at Y1 and Y3; non-significant changes were observed in fatigue and physical function mobility. Adults showed significant improvements in PRO measures of pain, stiffness, and physical function, with higher proportions of participants achieving minimal clinically important differences at Y3 vs Y1.

Trends observed in overall cohorts were generally consistent across age sub-groups, with statistical significance reached for many endpoints.

Conclusion

This analysis demonstrated the real-world effectiveness of burosumab for XLH, which appears evident across age groups.

Publication and source details

Original title: Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program

Leanne M Ward; Thomas O Carpenter; Hamilton Cassinelli; Pablo Florenzano; Erik A Imel; Aliya A Khan; Ben Johnson; Erru Yang; Marc Vincent; Heather M Heerssen; Zhiyi Li; Jill H Simmons

The Journal of Clinical Endocrinology and Metabolism · 2026

Correspondence: Leanne M. Ward, MD, FRCPC, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada K1H 8L1. Email: lward@cheo.on.ca.

On behalf of the XLH Disease Monitoring Program Investigators.

© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. Kyowa Kirin Inc.10.13039/501100004095 Kyowa Kirin10.13039/100016348 Ultragenyx Pharmaceutical10.13039/100013220 University of Ottawa10.13039/100008572 The Children’s Hospital of Eastern Ontario Research Institute10.13039/100031148

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:00:58.194449+00:00

DOI: 10.1210/clinem/dgag140 · PMC13467017